Skip to main content

Advertisement

SpringerLink
Log in

Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma

  • Thoracic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Definitive chemoradiation therapy or chemotherapy alone is generally recommended for patients with unresectable cT4b esophageal cancer. However, conversion surgery has emerged as a therapeutic option when downstaging is achieved by induction therapy.

Methods

We studied 169 patients with cT4 esophageal cancer who underwent induction therapy. Survival and prognostic factors were examined.

Results

Of 169 patients, 25 who achieved a clinical complete response (cCR) underwent surveillance, 72 patients underwent conversion surgery, while another 72 patients whose tumors were regarded as unresectable after induction therapy did not undergo surgery. Among 169 patients, the 3- and 5-year survival rates were 31.0% and 25.9%, respectively. Sixty-four patients who underwent curative resection showed better survival comparable with survival of 25 patients who achieved cCR (3- and 5-year survival; 56.8% and 48.6% versus 64.0% and 52.0%, respectively). However, the survival of eight patients who underwent noncurative resection was as dismal as that of patients who did not undergo conversion surgery. Multivariate analysis in 169 patients identified female sex and achieving cCR or R0 resection as independent prognostic factors. Multivariate analysis in 72 patients who underwent conversion surgery identified sex, lymph node status, and R0 resection as independent prognostic factors in patients with cT4b esophageal cancer.

Conclusions

The present study showed that conversion surgery after induction therapy can be a potentially curative treatment option for select patients with cT4b esophageal cancer. An important issue for further research is to establish a method for more accurately diagnosing tumor resectability after induction therapy for cT4b esophageal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086–1092.

    Article  CAS  Google Scholar 

  2. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007; 8: 226–234.

    Article  CAS  Google Scholar 

  3. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366: 2074–2084.

    Article  Google Scholar 

  4. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727–1733.

    Article  Google Scholar 

  5. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11–20.

    Article  CAS  Google Scholar 

  6. Miyata H, Yamasaki M, Miyazaki Y, et al. Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg. 2015; 262: 280–285.

    Article  Google Scholar 

  7. NCCN Guidelines Esophageal and Esophagogastric Junction Cancers, Version 2. 2018. Available at: https://www.nccn.org/patients.

  8. Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus 2017: The Japan Esophageal Society. Tokyo: Kanehara Shuppan; 2017.

    Google Scholar 

  9. Nishimura Y, Suzuki M, Nakamatsu K, Kanamori S, Yagyu Y, Shigeoka H. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys. 2002; 53: 134–139.

    Article  CAS  Google Scholar 

  10. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999; 17: 2915–2921.

    Article  CAS  Google Scholar 

  11. Cushman TR, Shaaban SG, Moreno AC, Lin C, Verma V. Management of Unresectable T4b Esophageal Cancer: Practice Patterns and Outcomes From the National Cancer Data Base. Am J Clin Oncol. 2019; 42: 154–159.

    Article  Google Scholar 

  12. Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004; 34:615–619.

    Article  Google Scholar 

  13. Kaneko K, Ito H, Konishi K, et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer. 2003; 88:18–24.

    Article  CAS  Google Scholar 

  14. Ikeda K, Ishida K, Sato N, et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus. 2001; 14:197–201.

    Article  CAS  Google Scholar 

  15. Noguchi T, Moriyama H, Wada S, et al. Resection surgery with neoadjuvant chemoradiotherapy improves outcomes of patients with T4 esophageal carcinoma. Dis Esophagus. 2003;16: 94–98.

    Article  CAS  Google Scholar 

  16. Van Raemdonck D, Van Cutsem E, Menten J, et al. Induction therapy for clinical T4 oesophageal carcinoma; a plea for continued surgical exploration. Eur J Cardiothorac Surg. 1997; 11: 828–837.

    Article  Google Scholar 

  17. de Manzoni G, Pedrazzani C, Pasini F, et al. Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol. 2007; 95: 261–266.

    Article  Google Scholar 

  18. Yano M, Shiozaki H, Tsujinaka T, et al. Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy. J Am Coll Surg. 2000;191: 626–634.

    Article  CAS  Google Scholar 

  19. Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016; 115:1328–1334.

    Article  CAS  Google Scholar 

  20. Motoori M, Yano M, Ishihara R, et al. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer. Ann Surg Oncol. 2012; 19: 2135–2141.

    Article  Google Scholar 

  21. Sugimura K, Miyata H, Yano M, et al. Is 18F-FDG-PET useful for predicting R0 resection after induction therapy for initially unresectable locally advanced esophageal carcinoma? Gen Thorac Cardiovasc Surg. 2017; 65: 455–462.

    Article  Google Scholar 

  22. Miyata H, Sugimura K, Yamasaki M, et al. Clinical Impact of the Location of Lymph Node Metastases After Neoadjuvant Chemotherapy for Middle and Lower Thoracic Esophageal Cancer. Ann Surg Oncol. 2019; 26: 200–208.

    Article  Google Scholar 

  23. Japanese Classification of Esophageal Cancer. 11th edition. The Japan Esophageal Society. Tokyo: Kanehara Shuppan; 2015.

    Google Scholar 

  24. Miyata H, Yamasaki M, Takiguchi S, et al. Prognostic value of endoscopic biopsy findings after induction chemoradiotherapy with and without surgery for esophageal cancer. Ann Surg. 2010; 253: 279–284.

    Article  Google Scholar 

  25. Brierley J, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours. 8th edition. Oxford: Wiley; 2017.

    Google Scholar 

  26. Ancona E, Ruol A, Castoro C, et al. First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up. Ann Surg. 1997; 226: 714–723.

    Article  CAS  Google Scholar 

  27. Ishikawa K, Nakamatsu K, Shiraishi O, Yasuda T, Nishimura Y. Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer. Int J Clin Oncol. 2015; 20: 531–537.

    Article  Google Scholar 

  28. Tachibana M, Dhar DK, Kinugasa S, et al. Surgical treatment for locally advanced (T4) squamous cell carcinoma of the thoracic esophagus. Dysphagia. 2002; 17: 255–261.

    Article  Google Scholar 

  29. Piessen G, Messager M, Mirabel X, et al. Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study. Ann Surg. 2013; 258: 793–799.

    PubMed  Google Scholar 

  30. Karimata H, Shimoji H, Nishimaki T. Clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer undergoing induction chemotherapy or chemoradiotherapy. Surg Today. 2015; 45: 479–486.

    Article  CAS  Google Scholar 

  31. van der Werf LR, Dikken JL, van der Willik EM, et al. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: a nationwide study. Eur J Cancer. 2018; 91: 76–85.

    Article  Google Scholar 

  32. Shaikh T, Ruth K, Scott WJ, et al. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg. 2015; 99: 270–276.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Digestive Surgery, Osaka International Cancer Institute, Osaka, Japan

    Hiroshi Miyata MD, Keijirou Sugimura MD, Masaaki Motoori MD, Takeshi Omori MD, Kazuyoshi Yamamoto MD, Yoshitomo Yanagimoto MD, Naoki Shinno MD, Masayoshi Yasui MD, Hidenori Takahashi MD, Hiroshi Wada MD, Masayuki Ohue MD & Masahiko Yano MD

Authors
  1. Hiroshi Miyata MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keijirou Sugimura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaaki Motoori MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takeshi Omori MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuyoshi Yamamoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshitomo Yanagimoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoki Shinno MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masayoshi Yasui MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hidenori Takahashi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiroshi Wada MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masayuki Ohue MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Masahiko Yano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Miyata MD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 15 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miyata, H., Sugimura, K., Motoori, M. et al. Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 26, 4737–4743 (2019). https://doi.org/10.1245/s10434-019-07727-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-07727-8

Search

Navigation